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Acute graft-versus-host disease (GVHD) occurs in 40% to 60% of recipients of partially matched umbilical cord
blood transplantation (UCBT). In a phase I study, adoptive transfer of expanded CD4þCD25þFoxp3þ natural
regulatory T cells (nTregs) resulted in a reduced incidence of grade II-IV acute GVHD. To investigate potential
mechanisms responsible for the reduced GVHD risk, we analyzed peripheral blood mononuclear cell mRNA
expression of a tolerance gene set previously identiﬁed in operation- tolerant kidney transplant recipients,
comparing healthy controls and patients who received nTregs and those who did not receive nTregs with and
without experiencing GVHD. Samples from patients receiving nTregs regardless of GVHD status showed
increased expression of Foxp3 expression, as well as B cellerelated tolerance marker. This was correlated with
early B cell recovery, predominately of naïve B cells, and nearly normal T cell reconstitution. CD8þ T cells
showed reduced signs of activation (HLA-DRþ expression) compared with conventionally treated patients
developing GVHD. In contrast, patients with GVHD had signiﬁcantly increased TLR5 mRNA expression,
whereas nTreg-treated patients without GVHD had reduced TLR5 mRNA expression. We identiﬁed
Lin-HLADR-CD33þCD16þ cells and CD14þþCD16 monocytes as the main TLR5 producers, especially in
samples of conventionally treated patients developing GVHD. Taken together, these data reveal interesting
similarities and differences between tolerant organ and nTreg-treated hematopoietic stem cell trans-
plantation recipients.
 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.þ þINTRODUCTION
The use of umbilical cord blood (UCB) as an alternative
source of hematopoetic stem cells (HSCs) for patients with
hematologic malignancies who require a potentially curative
allogeneic HSC transplantation (HSCT) but lack a suitable
related or unrelated adult donor has grown tremendously
[1]. Although the risk of severe acute and chronic graft-
versus-host disease (GVHD) is lower relative to the degree
of HLAmismatch, grade II acute GVHD in particular remains a
common complication after UCB transplantation (UCBT),
particularly in the setting of double UCBT [2-4]. It is well
known that B cell recovery is faster after UCBT than after, for
example, unrelated bone marrow transplantation [5].
Conversely, delayed T cell reconstitution has been reported
after UCBT [5]. Early reconstitution of natural killer (NK) cells
and CD4þ T cells after T cellereplete HSCT has been associ-
ated with protection from transplantation-related mortality
[6], whereas slow T cell recovery is considered to be associ-
ated primarily with deleterious infections, GVHD, and dis-
ease relapse [7].dgments on page 181.
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13.10.022Thymus-derived CD4 25 natural regulatory T cells
(nTregs) are central for the maintenance of immune ho-
meostasis and can prevent allograft rejection [8]. Thus,
clinical immunologists have strived to harness Tregs in novel
tolerance-promoting strategies for the prevention of GVHD
after HSCT, as well the prevention of rejection after solid
organ transplantation. Indeed, we previously demonstrated
in a ﬁrst-in-human clinical trial that infusion of polyclonally
ex vivo expanded nTregs was associated with a apparent
reduction in the incidence of grade II-IV GVHD with no
demonstrable deleterious effect on the risks of infection,
relapse, or early mortality in 23 nTreg-treated patients
compared with 108 historical controls [1].
Recently, a set of genes was described in which mRNA
expression in peripheral blood mononuclear cells (PBMCs)
distinguishes between tolerant kidney transplant recipients
and patients with chronic rejection [9]. This gene set contains
3 parameter groups. The ﬁrst group includes genes associated
with Treg composition. Foxp3, as their master transcription
factor, is highly expressed by CD4þCD25þ Tregs [8], whereas
expression of alpha-mannosidase (aMann) is increased in
CD45ROþ memory T cells [10]; thus, the Foxp3:aMann ratio
reﬂects the balance between Tregs and memory T cells. The
second group includes genes predominately or exclusively
expressed by B cells, such as CD20 (MS4A1); T cell leukemia/
lymphoma 1A (TCL1A), a transcriptional regulator andTransplantation. Published by Elsevier Inc. All rights reserved.
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expressed in naïve B cells [11,12]; Fc receptor-like 1/Fc
receptor-like 2 (FCRL1/FCRL2), immunoregulatory trans-
membrane proteins [13,14]; and prepronociceptin (PNOC), an
opioid-like receptor [15]. The third group contains genes
associated with composition or activation of innate immune
cells, such as Toll-like receptor-5 (TLR5), a pattern recognition
receptor recognizing bacterial ﬂagellin [16]; heparan sulfate
(glucosamine) 3-O-sulfotransferase 1 (HS3ST1), which is
highly expressed by NK cells/dendritic cells (DCs) and medi-
ates anti-inﬂammatory properties [17]; SH2 domain-
containing 1B (SH2D1B, or EAT-2), which regulates NK cell
cytotoxicity [18,19]; and solute carrier family 8 member 1
(SLC8A1, orNCX1), which regulates TNF-a production by
monocytes [20]. The differences in gene expression between
samples from tolerant and chronically rejecting kidney
transplant recipients reﬂect a relative andabsolute increase in
B cells, especially naïve (IgDþCD27) and transitional
(IgMþCD24þCD38þþ) B cells, and controlled innate immune
responses [9,21].
We investigated whether the expression of the tolerance
gene set also might reveal differences in recipients of nTregs
with or without GVHD after UCBT. Interestingly, nTreg infu-
sion, detectable for up to 2weeks post-transplantation, led to
high Foxp3mRNA expression in PBMCs analyzed at 6months
post-transplantation, regardless of the presence or absence
of GVHD. This in turn was associated with nearly normal T
cell frequencies compared with healthy controls. Similarly,
the expression of B cellerelated genes and reconstitution of
especially naïve B cells was higher in PBMC samples from
nTreg-treated patients. In contrast, expression of TLR5 was
signiﬁcantly different in nTreg-treated patients regardless of
the presence or absence of GVHD. TLR5 mRNA and protein
expression in PBMCs was lowest in nTreg-treated patients
without GVHD, whereas samples from conventionally
treated patients regardless of GVHD showed the highest
expression. Interestingly, Lin-HLADR-CD33þCD16þ cells and
CD14þþCD16 monocytes were identiﬁed as the main TLR5
producers in samples from patients receiving conventional
treatment. Thus, Treg treatment appears to reduce the fre-
quency of both TLR5high expressing subsets and the extend
of TLR5 expression in the former population and partially the
latter population. Our data reveal overlapping features in
tolerant solid organ transplant and nTreg-treated tolerant
UCBT recipients, reﬂecting the restoration of a healthy
“tolerant” balance between harmful and nonharmful leuko-
cyte subpopulations.
METHODS
Patient Inclusion Criteria
Patients with an advanced or high-risk hematologic malignancy were
eligible to receive UCB-derived Tregs if they met the following criteria: age
18 to 70 years with an available HLA 4-6/6 UCB graft containing 3.0  107
nucleated cells/kg, suitable organ function to allow a nonmyeloablative
regimen, and free of progressive fungal infection. In this study, all but 1 of
the patients received 2 partially HLA-matched UCB units as the HSC graft.
Because of the potential increased risk of sustained dual chimerism after
double UCBT, graft units were ABO-compatible, as described previously [1].
For this analysis, the UCBT recipients selected for analysis had sufﬁcient
numbers of stored cells at 6 months post-transplantation, were classiﬁed
with no GVHD versus grade I-IV acute GVHD, did or did not receive sup-
plemental Tregs as part of our phase I clinical trial, described below. No
other patient selection criteria were applied.
UCBT and Supportive Care
All patients received a conditioning regimen consisting of cyclophos-
phamide 50 mg/kg on day6, ﬂudarabine 40 mg/m2 daily on days6 to2,
and a single fraction of total body irradiation 200 cGy without shielding onday 1. All patients underwent UCBT, followed by administration of gran-
ulocyte colony-stimulating factor (Neupogen; Amgen, Thousand Oaks, CA)
5 mg/kg daily starting on day þ1 until an absolute neutrophil count >2500/
mL was achieved for 2 consecutive days. The second UCB unit was infused
within 30 minutes of the ﬁrst UCB unit. The study was approved by the
Institutional Review Board and registered at ClinicalTrials.Gov
(NCT00602693), and supportive care was applied following standard
guidelines as reported previously [1].
GVHD Prophylaxis with Treg Infusion and Pharmacologic Therapy
Patients were treated with 30  105 nTregs/kg actual body weight on
day þ2 (Table 1). No patient developed a dose-limiting toxicity. Patients
received mycophenolate mofetil (MMF) 1.5 g i.v. or orally twice daily from
day 3 to þ30 in combination with cyclosporine (CsA) twice daily, with a
target trough level of 200 to 400 ng/mL. Because CsA can potentially inter-
ferewith optimal Treg function and survival [22-24], the last cohort received
Tregs in the presence of sirolimus rather than CsA in combinationwithMMF.
Sirolimuswas given at a loading dose of 12mg followed by 4mg daily, with a
target trough level of 3 to 12 mg/mL from day 3 to day þ100. Tapering was
accomplished over the course of 8-12 weeks unless GVHD was diagnosed.
Manufacture of nTregs
nTregs were isolated from a partially HLA-matched third UCB unit
(provided by the New York Blood Center) that was 4-6/6 HLA-matched to
the recipient. Donor suitability was determined by current good
manufacturing practices. Institutional standard operating procedures were
followed to avoid cross-contamination. UCB units were thawed and pro-
cessed according to standard procedures [1,25]. Enrichment, culture, and
expansion of nTregs were performed as described previously [1].
Quantitative RT-PCR of Tolerance Set Genes
Total RNA from PBMCs of patients collected at 6 months and 1 year after
UCBT was isolated using the NucleoSpin RNA II Kit (Machery-Nagel, Düren,
Germany). For this, 200 ng of whole-blood total RNA was reverse-
transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, Hil-
den, Germany), and synthesized cDNAwas subjected to quantitative RT-PCR
(qRT-PCR) analysis. qRT-PCR was performed for the following genes using
premade TaqMan Gene Expression Assays (Life Technologies, Carlsbad, CA):
Hs01099196_m1 HS3ST1, Hs01592483_m1 SH2D1B, Hs00172040_m1
TCL1A, FCRL2, FCRL1, MS4A1, (Immunoglobulin-Associated Beta), PNOC, TLR5,
and SLC8A1, or self-designed panels: Foxp3, aMann, and hypoxanthine
guanine phosphoribosyl transferase (HPRT), which served as a house-
keeping gene. Gene expression was determined by the DDCT method as
described previously [9,26].
Flow Cytometry
Thawed PBMCs collected at the same time as samples for qRT-PCR
were washed and resuspended at 1  106/mL. Titrated amounts of
ﬂuorochrome-conjugated monoclonal antibodies were used to identify the
following leukocyte subsets: CD45þCD14 for lymphocytes, CD3þ for T
cells, CD19þ for B cells, CD56þ/CD16þCD3 for NK cells, CD4þCD3þHLA-
DRþ/ for CD4 T cells, CD8þCD3þHLA-DRþ/ for CD8 T cells, CD14þþ/
dimCD16/þ for monocytes, and CD3-CD19-CD56-CD14-HLA-DRþ for DCs.
Antibody conjugates were obtained from BD Biosciences (Heidelberg,
Germany) or Beckman Coulter (Krefeld, Germany). Samples were costained
with antieTLR5-FITC (IMG-663C; Imgenex, San Diego, CA) using Cytoﬁx/
Cytoperm staining solutions (BD Biosciences). B cell subsets were deﬁned
as IgDþCD27- naive B cells, IgD-IgM-CD27þ memory B cells, and
IgMþCD24þCD38þþ transitional B cells. Cells were ﬁxed with 1% para-
formaldehyde/PBS, and data were acquired with an LSR II ﬂow cytometer
(BD Biosciences) within 24 hours.
Statistical Analysis
Nonparametric tests were used to estimate statistical signiﬁcance,
because the patient numbers were lowand data did not conform to a normal
distribution. The Wilcoxon signed-rank test was used to compare responses
within the same group of patients, and the Mann-Whitney U test was used
to compare medians between patient groups.
RESULTS
Clinical Outcomes
Treg doses, GVHD prophylaxis, and grading characteris-
tics of analyzed patient groups are presented in Table 1. All
patients who did not receive nTregs were treated with
CsA for GVHD prophylaxis. Of the patients studied, 4 of 6
nTreg-treated patients without GVHD received sirolimus for
Table 1
Patient Characteristics
Patient nTreg Dose
(Day of Infusion)
GVHD Prophylaxis Maximum GVHD Grade
(Day of Onset)
GVHD Organ(s) Chronic GVHD
(Day of Onset)
no Tregs/no GVHD #1 None CsA/MMF None None No
no Tregs/no GVHD #2 None CsA/MMF None None No
no Tregs/no GVHD #3 None CsA/MMF None None No
no Tregs/no GVHD #4 None CsA/MMF None None No
no Tregs/no GVHD #5 None CsA/MMF None None No
no Tregs/no GVHD #6 None CsA/MMF None None No
no Tregs/no GVHD #7 None CsA/MMF None None No
no Tregs/no GVHD #8 None Rapamycin/MMF None None No
no Tregs/no GVHD #9 None CsA/MMF None None No
no Tregs/no GVHD #10 None CsA/MMF None None No
no Tregs/GVHD #1 None CsA/MMF III (14) Skin, lower GI Yes (125)
no Tregs/GVHD #2 None CsA/MMF III (44) Lower GI No
no Tregs/GVHD #3 None CsA/MMF III (27) Lower GI, upper GI No
no Tregs/GVHD #4 None CsA/MMF II (37) Skin No
no Tregs/GVHD #5 None CsA/MMF II (28) Skin Yes (104)
no Tregs/GVHD #6 None CsA/MMF III (29) Skin, lower GI No
no Tregs/GVHD #7 None CsA/MMF III (21) Skin, lower GI, upper GI Yes (133)
no Tregs/GVHD #8 None CsA/MMF III (49) Skin, lower GI No
no Tregs/GVHD #9 None CsA/MMF IV (44) Skin, lower GI No
Tregs/no GVHD #1 3  106 (2) CsA/MMF None None No
Tregs/no GVHD #2 3  106 (2) Rapamycin/MMF None None No
Tregs/no GVHD #3 3  106 (2) Rapamycin/MMF None None No
Tregs/no GVHD #4 3  106 (2) Rapamycin/MMF None None No
Tregs/no GVHD #5 3  106 (2) Rapamycin/MMF None None No
Tregs/no GVHD #6 3  106 (2) CsA/MMF None None No
Tregs/GVHD #1 3  106 (1) CsA/MMF II (41) Skin No
Tregs/GVHD #2 3  106 (2) CsA/MMF II (37) Skin Yes (1009)
Tregs/GVHD #3 3  106 (2) CsA/MMF II (29) Skin No
Tregs/GVHD #4 3  106 (2) CsA/MMF II (21) Skin No
Tregs/GVHD #5 3  106 (2) Rapamycin/MMF III (86) Skin, lower GI No
Tregs/GVHD #6 3  106 (2) CsA/MMF II (39) Skin, upper GI No
GI indicates gastrointestinal tract.
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GVHD were treated with CsA.
High PBMC Foxp3 and B CelleRelated Gene Expression
Levels In Patients Without GVHD and Their Relationship
to nTreg Therapy
PBMC samples were collected at 6 months post-
transplantation from the following patient groups: non-nTreg
patients without GVHD (n ¼ 10), non-nTreg patients with
GVHD (n ¼ 9), nTreg-treated patients without GVHD (n ¼ 6),
nTreg-treatedpatientswithGVHD (n¼ 6), andhealthycontrols
(n¼ 10). These sampleswere analyzed formRNAexpression of
the recently described indices of tolerance (IOT) gene set,
comparing biomarkers for group 1 (Treg-associated genes),
group 2 (B celleassociated genes), and group 3 (genes associ-
ated with innate immune cell function) genes [9].
With respect to the group 1 biomarker FoxP3, the FoxP3
mRNA levels in PBMCs were signiﬁcantly higher in nTreg-
treated patients without GVHD compared with nonenTreg-
treated patients with GVHD at 6 months post-UCBT
(Figure 1). As we reported previously [1], we detected
infused nTregs for only up to 14 days postinfusion; thus, we
attribute the high FoxP3 expression to an indirect effect of
elimination of GVHD in the context of nTreg infusion.
Samples from nTreg-treated patients without aGVHD also
demonstrated increased expression of B cellerelated genes,
such as MS4A1, TCL1A, CD79b, PNOC, FCRL1, and FCRL2,
compared with samples from nonenTreg-treated patients
developing GVHD (Figure 1). Because conventionally patients
without GVHD had similar increased early expression of B
cellerelated genes as nTreg-treated patients without GVHD,
the observed solid organ B cell tolerance signature was
reﬂective of GVHD status and not of nTreg infusion per se.We next investigated whether the high expression of
Foxp3 and B cellerelated genes in samples from nTreg-
treated patients without GVHD were related to differences
in immunosuppressive maintenance therapy. Expression
results from samples of nTreg-treated patients with or
without acute GVHD were plotted according to CsA- or
sirolimus-based maintenance therapy (Supplemental
Figure 1). The results clearly show similar expression of
Foxp3 in samples from nTreg-treated patients on CsA-based
maintenance therapy and those on sirolimus-based mainte-
nance therapy. Expression of MS4A1, FCRL1, and FCRL2 was
reduced in samples from some CsA-treated patients; how-
ever, the difference did not reach statistical signiﬁcance and
was seen in only 3 patients, all of whom developed GVHD.
Decreased TLR5 mRNA Expression in PBMCs of nTreg-
Treated Patients without GVHD
With regard to group 3 biomarkers, no differences be-
tween groups were seen in expression of SH2D1B, regu-
lating NK cell cytotoxicity [18,19], and SLC8A1, regulating
TNF-a production by monocytes [20] (Figure 1). In contrast,
we observed increased mRNA expression at 6 months post-
UCBT in PBMCs for HS3ST1 (highly expressed by NK cells/
CD33þ DCs and mediating anti-inﬂammatory properties)
expression in samples from both nTreg-treated and non-
enTreg-treated patients without GVHD compared with
healthy controls or conventionally treated GVHD patients
(Figure 1). Although nTreg infusion did not further increase
HS3ST1 levels in patients without GVHD, nTreg-treated
patients with GVHD had higher trending HS3ST1 levels
(P ¼ .06) compared with conventionally treated patients
with GVHD, suggesting an effect of previous nTreg infusion
on HS3ST1 level.
Figure 1. Expression of transplant toleranceeassociated genes. mMRNA expression of IOT genes was analyzed in PBMCs of patients undergoing UCBT under con-
ventional immunosuppressive treatment who did not develop GVHD (non-nTreg/no GVHD; n ¼ 10), patients undergoing UCBT under conventional immunosup-
pressive treatment who developed GVHD (non-nTreg with GVHD; n ¼ 9) or additional nTreg transfer with (nTreg with GVHD; n ¼ 6) or without development of
GVHD (nTreg no GVHD; n ¼ 6) at 6 months post-transplantation, and of healthy controls (n ¼ 10) by qRT-PCR as described in Materials and Methods. Data are shown
as log-transformed gene expression values calculated in relation to the housekeeping gene HPRT. *P  .05; **P  .01; ***P  .001.
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from nTreg-treated patients without GVHD compared with
nonenTreg-treated patients with GVHD (Figure 1). Only in the
nTreg-treated patients without GVHD did TLR5 expression
normalize, reaching signiﬁcantly lower levels compared with
those seen in healthy controls. We investigated whether this
effect was inﬂuenced by the sirolimus-based maintenance
therapy as well. Indeed, TLR5 expression was increased in
samples from some CsA-treated patients (Supplemental
Figure 1); however, this increase did not reach statistical sig-
niﬁcance and was seen in only 3 patients, all of whom devel-
oped GVHD, but was not seen in any of the 4 patients without
GVHD. These data suggest that in GVHD-free patients, nTreg
infusion coupled with sirolimus- or CsA-based maintenance
therapy conferred sufﬁcient tolerization to normalize TLR5
expression levels.
Conventionally Treated Patients with GVHD Have a Low
Frequency of Adaptive Immune Cells with a High
Frequency of Innate Immune Cells
Because the tolerance gene set identiﬁed in tolerant solid
organ transplant recipients corresponded with the altered
composition of blood leukocyte subsets, we also studied
whether nTreg treatment results in modiﬁed leukocytereconstitution after UCBT. The leukocyte subset distribution
in samples from UCBT recipients and healthy controls is
shown in Figure 2. Samples from all transplant recipients
regardless of group showed reduced T cell frequencies
compared with controls (Figure 2A); however, samples from
conventionally treated patients with GVHD had the lowest
frequency of T cells. Treatment with nTregs resulted in a
higher absolute number of CD3þ T cells, especially compared
with that seen in conventionally treated patients with GVHD
(Supplemental Figure 2). Total NK cell frequencies were
greatest in samples from conventionally treated patients
with GVHD (Figure 2D), although absolute numbers were
comparable in all groups. Samples from both patient groups
with GVHD contained more monocytes early after trans-
plantation compared with healthy controls, but not signiﬁ-
cantly higher compared with samples from patients without
GVHD (Figure 2C). The relative proportion of DCs was
increased in all patient groups compared with healthy con-
trols (Figure 2E); however, there were no differences among
the patient groups in the total DC population or in myeloid or
plasmacytoid subpopulations (data not shown). Finally,
normal B cell frequencies and absolute numbers were found
in all patient groups except conventionally treated patients
with GVHD (Figure 2B).
Figure 2. Distribution of leukocyte subsets in peripheral blood. Frequencies of (A) T cells (CD3þ), (B) B cells (CD19þ), (C) monocytes (CD14þ), (D) NK cells (CD3,
CD19, and CD16þ), and (E) DCs (CD3-CD19-CD16-CD14-HLA-DRþ) in PBMCs of patients undergoing UCBT under conventional immunosuppressive treatment whjo
did not develop GVHD (non-nTreg/no GVHD; n ¼ 10), patients undergoing UCBT under conventional immunosuppressive treatment who developed GVHD (non-
nTreg with GVHD; n ¼ 9) or additional nTreg transfer with (nTreg with GVHD; n ¼ 6) or without development of GVHD (nTreg/no GVHD; n ¼ 6) at 6 months post-
transplantation, and of healthy controls (n ¼ 10) were determined as described in Materials and Methods. *P  .05; **P  .01; ***P  .001; ****P  .0001.
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Conventionally Treated Patients with GVHD
Because the expression of B cellerelated genes from the
IOT tolerance gene set was lowest and the absolute total
B cell count was dramatically reduced in conventionally
treated UCBT recipients with GVHD, we investigated
whether the distribution of B cell subsets differed in this
group as well. We analyzed the frequencies of transitional
(CD19þIgMþCD38þþ; Figure 3A), naive (CD19þIgDþCD27;
Figure 3B), and memory (CD19þIgM-CD27þ; Figure 3C) B
cells within the CD19þ cell compartment. B cells from
conventionally treated transplant recipients with GVHD
demonstrated signiﬁcantly reduced frequencies of naïve B
cells, but increased frequencies of memory B cells
compared with all other patient groups. In contrast, nTreg-
treated patients with GVHD had similar frequencies of
naïve and memory B cells as those without GVHD. The
relative proportions of transitional B cells were higher in
samples from patients without GVHD regardless of nTreg
treatment.Impact of nTreg Treatment on CD56high NK Cells and
Activated HLA-DRþ T Cells
We also studied whether transfer of nTregs affected the
number of CD56high NK cells, which produce abundant
cytokines, and activated T cells. As shown in Figure 4A,
samples from all patient groups contained more CD56high
NK cells compared with samples from healthy controls.
This difference was most dramatic for conventionally
treated patients developing GVHD, but was not sufﬁciently
inﬂuenced by nTreg transfer. To study differences in the
numbers of activated T cells, we assessed the frequencies
of HLA-DRþCD4þ and CD8þ T cells, as has been done pre-
viously after stem cell transplantation [27-29]. UCBT re-
cipients are characterized by higher percentages of
activated HLA-DRþ cells within the CD4þ and CD8þ T cell
compartments compared with samples from healthy
controls, al though statistical signiﬁcance was reached
only for noneTreg-treated patients (Figure 4B and C). For
CD4þ T cells, this effect was largely independent of the
development of GVHD. In contrast, samples from
Figure 3. Distribution of B cell subsets in peripheral blood. Frequencies of (A) transitional B cells (CD19þIgMþCD38þþ), (B) naïve B cells (CD19þIgDþCD27), and (C)
memory B cells (CD19þIgM-CD27þ) in PBMCs of patients undergoing UCBT under conventional immunosuppressive treatment who did not develop GVHD (non-
nTreg/no GVHD; n ¼ 10), patients undergoing UCBT under conventional immunosuppressive treatment developing GVHD (non-nTreg with GVHD; n ¼ 9) or addi-
tional Treg transfer with (nTreg with GVHD; n ¼ 6) or without development of GVHD (nTreg/no GVHD; n ¼ 6) at 6 months post-transplantation, and of healthy
controls (n ¼ 10) were determined as described in Materials and Methods. *P  .05; **P  .01.
B. Sawitzki et al. / Biol Blood Marrow Transplant 20 (2014) 173e182178conventionally treated patients with GVHD contained the
highest proportion of HLA-DRþCD8þ T cells. Interestingly,
nTreg transfer seemed to counteract GVHD-associated
generation of HLA-DRþCD8þ T cells despite the develop-
ment of GVHD.Figure 4. Distribution of NK and T cell subsets in peripheral blood. Frequencies of
(CD4þHLA-DRþ) and (C) CD8þ T cells (CD8þHLADRþ) in PBMCs of patients undergoing
GVHD (non-nTreg/no GVHD; n ¼ 10), patients undergoing UCBT under conventional
n ¼ 9) or additional nTreg transfer with (nTreg with GVHD; n ¼ 6) or without developm
healthy controls (n ¼ 10) were determined as described in Materials and Methods. *Identiﬁcation of Lin-CD33þ Granulocyte-Like and CD16
Monocytes as Main TLR5 Producers
We next sought to determine which leukocyte subset
contributes to the increased TLR5 expression in patients who
develop GVHD. TLR5 staining of PBMCs from a conven-
tionally treated patient with GVHD revealed bimodal(A) CD56bright NK cells (CD3-CD16dimCD56high) and (B) activated CD4þ cells
UCBT under conventional immunosuppressive treatment who did not develop
immunosuppressive treatment who developed GVHD (non-nTreg with GVHD;
ent of GVHD (nTreg no GVHD; n ¼ 6) at 6 months post-transplantation, and of
P  .05; **P  .01; ***P  .001.
Figure 5. TLR5 expression in leukocyte subsets. Shown are representative histogram plots of TLR5 expression in whole PBMCs (A); lymphocytes versus CD14þ
monocytes, DCs, and CD3-CD19-CD56-CD14-HLA-DR-CD33þCD16þ cells (B); CD3-CD19-CD56-CD14-HLA-DR-CD33þCD16þ cells from representative samples of all
patient groups and healthy controls (C); and CD14þþCD16- versus CD14þþCD16þ and CD14þCD16þþ monocytes (D), measured as described in Materials and
Methods.
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and especially a subset of CD3-CD19-CD56-CD14-HLA-
DR-CD33þCD16þ cells compared with lymphocytes and DCs
(Figure 5B). As indicated by their surface expression, the
latter population is distinct from lymphocytes and mono-
cytes (CD3-CD19-CD56-CD14- lineage-negative), as well as
from DCs (HLA-DR-). Interestingly, the TLR5 expression
of CD3-CD19-CD56-CD14-HLA-DR-CD33þCD16þ cells was
highest in samples from conventionally treated patients
regardless of the presence or absence of GVHD, whereas a
large proportion of this cell subset showed low TLR5
expression in samples from nTreg-treated patients
(Figure 5C). Furthermore, the percentage and phenotype of
those CD3-CD19-CD56-CD14-HLA-DR-CD33þCD16þ cells
differed in samples from nTreg-treated patients and
conventionally treated patients (Supplemental Figure 3).
The numbers were reduced and characterized by higher
CD16 expression compared with samples from conven-
tionally treated patients. Subgating identiﬁed CD16low-
expressing cells as the main TLR5-expressing cells (data not
shown).
Peripheral monocytes have been subdivided into 3
subpopulations based on the relative expression level of
CD14 and the presence of CD16: CD14þþCD16,
CD14þþCD16þ, and CD14þCD16þþ monocytes [30]. These
monocyte subsets have different functional properties, with
CD14þþCD16 and CD14þþCD16þ being more inﬂammatory
and CD14þCD16þþ exhibiting patrolling properties [31]. Our
subset analyses revealed that particularly high TLR5
expression in the inﬂammatory CD14þþCD16- monocytes
(Figure 5D).Reduced CD16- Monocytes in Samples from nTreg-Treated
Patients without GVHD
PBMCs of UCBT recipients with GVHD demonstrated
signiﬁcantly higher frequencies of CD14þþCD16monocytes
compared with PBMCs from patients without GVHD and
healthy controls (Figure 6A). In contrast, frequencies of both
CD16-expressing monocyte subsets were signiﬁcantly
decreased in samples from patients with GVHD (Figure 6B
and C).
We next studied the TLR5 surface expression of all 3
monocyte subsets in samples from UCBT recipients and
healthy controls (Figure 7). As shown in Figure 5,
CD14þþCD16 monocytes in general demonstrated the
strongest TLR5 expression. Interestingly, CD14þþCD16
monocyte subsets from both nTreg-treated patient groups
exhibited the lowest TLR5 expression.
Again we investigated whether the composition of
monocyte subsets and TLR5 protein expression was also
inﬂuenced by the sirolimus-based maintenance therapy.
Although samples from nTreg-treated patients receiving
CsA-based maintenance therapy showed a tendency toward
more CD14þþCD16 monocytes, this trend did not reach
statistical signiﬁcance (Supplemental Figure 4A). Further-
more, TLR5 expressionwas lower in CD16þþmonocytes from
nTreg-treated patients receiving sirolimus-based mainte-
nance therapy, but the difference was not statistically sig-
niﬁcant (Supplemental Figure 4B).
DISCUSSION
Our data fromanalysis of a recently described IOT tolerance
gene set show that nTreg treatment resulted in high Foxp3
Figure 6. Distribution of monocyte subpopulations. Frequencies of CD14þþCD16 (A), CD14þþCD16þ (B), and CD14þCD16þþ monocytes (C) in PBMCs of patients
undergoing UCBT under conventional immunosuppressive treatment who did not develop GVHD (non-nTreg/no GVHD; n ¼ 10), patients undergoing UCBT under
conventional immunosuppressive treatment who developed GVHD (non-nTreg with GVHD; n ¼ 9) or additional nTreg transfer with (nTreg with GVHD; n ¼ 6) or
without development of GVHD (Treg no GVHD; n ¼ 6) at 6 months post-transplantation, and of healthy controls (n ¼ 10) were determined as described in Materials
and Methods. *P  .05; **P  .01.
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cells after UCBT, especially in patients who did not develop
GVHD (Figures 1 and 2 and Supplemental Figure 2). Only
samples from conventionally treated patients with GVHD
exhibited reduced expression levels of B cell-related IOTgenes,
such as MS4A1 and TCL1A (Figure 1). This result was not
observed in samples from nTreg-treated patients with GVHD.
Conventionally treated patients with GVHD demonstrated
reduced relative and absolute B cell numbers and a shift from
the naïve to memory phenotype, which was prevented byFigure 7. TLR5 expression in individual leukocyte subpopulations. TLR5
expression depicted as mean ﬂuorescence intensity in monocyte subsets from
PBMCs of patients undergoing UCBT under conventional immunosuppressive
treatment who did not develop GVHD (non-nTreg/no GVHD; n ¼ 10), patients
undergoing UCBT under conventional immunosuppressive treatment who
developed GVHD (non-nTreg with GVHD; n ¼ 9) or additional nTreg transfer
with (nTreg with GVHD; n ¼ 6) or without development of GVHD (nTreg/no
GVHD; n ¼ 6) at 6 months post-transplantation, and of healthy controls
(n ¼ 10) were determined as described in Materials and Methods. *P  .05.nTreg infusion (Figures 2 and 3 and Supplemental Figure 2).
Samples from conventionally treated patients with GVHD
contained more TLR5, which was expressed at the highest
levels on CD3-CD19-CD56-CD14-HLA-DR-CD33þCD16þ cells
and CD14þþCD16- monocytes (Figures 1, 5, 6, and 7 and
Supplemental Figures 2 and 3), whereas samples from
nTreg-treated patients without GVHD had the lowest TLR5
expression, even lower than that seen in healthy controls.
It was reported previously, and we have conﬁrmed it in
this study, that HSCT recipients who develop GVHD have
signiﬁcantly lower numbers of naïve B cells, but increased
levels of CD27-expressing memory/activated B cells [32-35].
We also detected an increased proportion of CD56high NK
cells in conventionally treated patients with GVHD. Samples
of those patients contained lower numbers of T cells as well.
Indeed, Vukicevic et al. [36] detected increased numbers of
such NK cells after HSCT in patients with low T cell numbers.
TLR5 expression, reportedly increased in samples from
chronically rejecting kidney transplant recipient, was signiﬁ-
cantly reduced in our nTreg-treated UCBT recipients without
GVHD (Figures 1 and 3). Thus, lowTLR5 expressionwas seen in
both tolerant solid organ as well as nTreg-treated UCBT re-
cipients without GVHD. We performed the ﬁrst-reported
extensive TLR5 expression analysis in leukocyte subsets,
identifying CD3-CD19-CD56-CD14-HLA-DR-CD33þCD16þ cells
and monocytes, particularly CD14þþCD16monocytes, as the
highest TLR5-expressing leukocyte subset (Figure 5). Of the
former, the CD16low subset was characterized by particularly
high TLR5 expression (Figure 5 and data not shown). Indeed,
samples fromconventionally treatedpatients containedhigher
levels of these CD16low cells (Supplemental Figure 3). The
CD33þCD16low cells detected in our samples are apparently
identical to the recently described CD16low granulocytic subset
[37-39]. Indeed, it is known that granulocytes exhibit reduced
CD16 surface expression during activation [40,41]. Thus, the
reduced frequency of CD16low TLR5high-expressing cells in
B. Sawitzki et al. / Biol Blood Marrow Transplant 20 (2014) 173e182 181nTreg-treated patients compared with conventionally treated
patients indicates reduced inﬂammation as a direct effect of
Treg treatment.
Qian et al. [42] reported that an age-related increase in
TLR5þ monocytes is associated with an increased inﬂam-
matory response, although they did not discriminate be-
tween CD16þ and CD16 monocytes. Increased peripheral
and colonic TLR5 expression has been reported in patients
with inﬂammatory bowel disease [43,44] and patients with
ankylosing spondolytis [45]. Skert et al. [46] detected higher
TLR5 expression on T cells, especially monocytes, in patients
with aGVHD, although they did not further discriminate
between CD16þ and CD16 monocytes.
Ziegler-Heitbrock [30] ﬁrst suggested that the differential
expression of CD16 could deﬁne at least 2 separate subsets of
monocytes with distinct properties [47]. CD14þCD16þþ
monocytes have a tissue-patrolling function and respond
weakly to bacterial TLR ligands [31]. Smeekens et al. [48]
compared the Th17-promoting capacities of CD14þþCD16
and CD14þCD16þþmonocytes and found that although both
monocyte subsets were able to phagocytose and kill Candida
albicans, only CD14þþCD16 induced a potent Th17 response.
Rommeley et al. [49] reported an association between
increased numbers of reconstituted CD16-expressing
monocytes and reduced risk for GVHD. Thus, effective
GVHD prophylaxis with Tregsmay favor the reconstitution of
CD14þCD16þþ or CD14þþCD16þ monocytes, which express
less TLR5 and exert greater tissue-patrolling and repair
functions compared with CD14þþCD16 monocytes, which,
owing to their increased TLR and CD14 expression, are ready
to respond to inﬂammatory signals, such as endogenous and
exogenous TLR ligands. This may lead to a reduced risk for
GVHD.
Because our nTreg-treated patients without GVHD were
treated predominantly with sirolimus, instead of CsA as used
in nonenTreg-treated patients and nTreg-treated patients
with GVHD, we cannot discern whether some of our
discriminatory ﬁndings, such as stably decreased peripheral
TLR5 expression, were related to the use of sirolimus, nTregs,
or both in combination.
Nonetheless, our ﬁndings indicate that UCBT recipients
treated with nTregs combined with sirolimus have a robust
tolerance signature that mirrors that of tolerant solid organ
transplant recipients. Of note, sirolimus has been reported to
favor the development and induction of Tregs, in contrast to
CsA [50]. Sirolimus, but not CsA, preserves the highly sup-
pressiveCD27þ subsetofhumanCD4þCD25þ regulatoryTcells
[22]. Moreover, in preclinical models, sirolimus is compatible
with Treg-mediated suppression of GVHD, but CsA is not
[24,51]. Thus, it is distinctly possible that sirolimus accentu-
ated the tolerance signature of nTreg infusion in the context of
UCBT by permitting a higher frequency and biological potency
of nTregs early post-transplantation comparedwith CsA, or by
inducing Tregs from a CD4þCD25 non-nTreg population
infused in the UCB graft. However, of note, 2 studies using
nonmyeloablative conditioning and matched related donors
along with the GVHD prophylaxis with MMF plus sirolimus
found a high incidence of acute GVHD, causing the premature
cessation of one study because of excessive acute GVHD (C.
Cutler, personal communication, Department of Medical
Oncology, Dana-Farber Cancer Institute) and discontinuation
of the other owing to a combination of a high aGVHD rate and
excessive toxicity [52].
Moreover, our investigation also revealed that CD14þþ
CD16 monocytes of nTreg-treated patients with or withoutGVHD showed lower TLR5 expression per cell early after UCBT
(Figure 7). In addition, as pointed out earlier, faster B cell
reconstitution of predominantly naïve B cells and increased B
cellerelated gene expression were observed in samples from
nTreg-treated patients despite the development of GVHD,
which was not seen in samples from conventionally treated
patients with GVHD (Figures 1, 2, and 3). Future studies in
which patients are givenTregs or noTregs and either sirolimus
or CsAwith MMF are needed to resolve this issue.
Our data reveal similarities between tolerant solid organ
transplant recipients andnTreg- andpredominantly sirolimus-
treated UCBT recipients without GVHD, characterized by low
peripheral TLR5 expression and an altered balance of poten-
tially nonharmful (eg, CD14þCD16þþTLR5low) and harmful (eg,
CD14þþCD16-TLR5high) leukocyte subpopulations. This ﬁnding
may reﬂect a direct effect of Tregs on the differentiation of
CD16-expressingmonocytes. In future investigations, itwill be
important to unravel the communication between Tregs and
monocyte subpopulations in more detail to permit the thera-
peutic use of this mode of action. Our results provide an
essential diagnostic basis for validation in future studies,
particularly in safe drug weaning and Treg treatment trials in
solid organ and HSC transplantation.ACKNOWLEDGMENTS
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